ANGIODYNAMICS INC
AngioDynamics is a medical technology company that designs, manufactures and sells products used by clinicians treating patients with cardiovascular disease and cancer. Headquartered in Latham, N.Y., it focuses its sales and marketing on interventional radiologists and cardiologists, vascular surgeons, urologists, oncologists and critical care nurses. It sells in the United States primarily through a direct sales force and internationally through direct sales and distributors. Its products are organized into Med Tech and Med Device segments. Med Tech includes the Auryon atherectomy system, thrombectomy devices, thrombolytic catheters and the NanoKnife ablation system. Med Device includes peripheral procedure products such as angiographic catheters, guidewires, drainage catheters and micropuncture kits, as well as ports, venous insufficiency treatments, microwave ablation systems and radiation therapy balloons. AngioDynamics makes money by selling these medical devices and related procedure kits and accessories.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
AngioDynamics Inc. (ANGO) filed an SEC Form 3. Historical data shows mixed stock performance post-headlines, with median moves of 1.9%. Recent events include conference participation, study results, and financial reports.
Trowbridge Stephen A (EVP and CFO) sold 25,335 shares of ANGIODYNAMICS INC (ANGO) at an average of $12.26 ($12.17–$12.27, $0.31M total) across 2 trades over 2026-10-28 to 2026-10-29.
AngioDynamics reported study results linking IRE to longer survival in Stage III PDAC. The AMA approved a new CPT code for open pancreatic IRE, effective 2027. The company aims to strengthen IRE's clinical and reimbursement foundation.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ANGO (ANGIODYNAMICS INC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent ANGO coverage spans earnings, financial news and insider activity.
In the last 30 days, ANGO insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($311K). The most active reporter was Trowbridge Stephen A, EVP and CFO, with 2 filings.
Minor market reaction expected as the filing provides limited new information on insider holdings.
The insider sale may signal personal liquidity needs or lack of confidence, creating modest downside pressure.
The trial data and CPT code suggest future reimbursement growth, likely boosting the stock.
Coverage expansion likely improves sales outlook for NanoKnife.
The earnings miss and target cut suggest further downside pressure on ANGO.
AlphAI scores every news story that mentions ANGO with an AI model for sentiment and relevance, and aggregates insider trades from ANGIODYNAMICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
AngioDynamics Inc. (ANGO) filed an SEC Form 3. Historical data shows mixed stock performance post-headlines, with median moves of 1.9%. Recent events include conference participation, study results, and financial reports.
Trowbridge Stephen A (EVP and CFO) sold 25,335 shares of ANGIODYNAMICS INC (ANGO) at an average of $12.26 ($12.17–$12.27, $0.31M total) across 2 trades over 2026-10-28 to 2026-10-29.
AngioDynamics reported study results linking IRE to longer survival in Stage III PDAC. The AMA approved a new CPT code for open pancreatic IRE, effective 2027. The company aims to strengthen IRE's clinical and reimbursement foundation.
AngioDynamics announced that Humana updated its Medicare Advantage coverage policy to include NanoKnife IRE for prostate and liver cancer, effective October 1, 2026. This follows recent reimbursement milestones, including new CPT codes and Palmetto GBA's LCD L40205. Humana, with 7 million members, will use LCD L40205 criteria for coverage, subject to prior authorization.
H.C. Wainwright reduced its price target for AngioDynamics (ANGO) to $18 from $19, maintaining a Buy rating. The company reported fiscal Q1 2027 net sales of $80.9M, up 6.9% YoY, but a net loss of $7.1M. Guidance for fiscal 2027 includes revenue of $336M-$341M and adjusted EBITDA of $13M-$16M. Canaccord Genuity reiterated its Buy rating with a $20 target, citing growth in key platforms. The stock fell 23% post-earnings.
AngioDynamics reported Q1 fiscal 2027 revenue of $80.9M, up 6.9% YoY. Med Tech revenue grew 13.2% to $39.9M, while Med Device revenue rose 1.4% to $41M. Gross margin expanded to 59.4%. The company reported a GAAP net loss of $7.1M, improving from last year. Adjusted EBITDA increased to $5M. AngioDynamics reiterated its full-year revenue guidance of $336M to $341M.
Canaccord Genuity kept a Buy rating on AngioDynamics with a $20 price target, suggesting a 78.1% upside. The company reported $80.9M revenue, up 6.9% YoY, and expects positive cash flow for the fiscal year.
AngioDynamics (NASDAQ: ANGO) reported Q1 FY2027 net loss of $7.1M, down from $10.9M YoY. Net sales rose 6.9% to $80.9M, with Med Tech sales up 13.2%. Adjusted EBITDA was $5.0M. The company announced Eric Honroth as new CEO, effective November 2, 2026. FDA approved IDE for RELIEF study on NanoKnife IRE for benign prostatic hyperplasia. Guidance reiterated: net sales $336M-$341M, adjusted EBITDA $13M-$16M.
ANGIODYNAMICS INC (ANGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability Delivered its eighth consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA LATHAM, N.Y.--(BUSINESS
ANGIODYNAMICS INC (ANGO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 NEWS RELEASE Investor Contact: Stephen Trowbridge Executive Vice President & CFO 518-795-1408 strowbridge@angiodynamics.com Media Contact: Saleem Cheeks Vice President, Communications 518-795-1174 scheeks@angiodynamics.com AngioDynamics Announces Appointment of Eric
